MKMisako Kaido

Misako Kaido

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Misako Kaido has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Harutoshi Fujimura

    Department of Neurology and Pathology National Hospital Organization Osaka Toneyama Medical Center Toyonaka Japan

    2 shared publications
  • Yoshihito Yuasa

    Department of Neurology Sakai City Medical Center Sakai City Osaka Japan

    2 shared publications
  • Iwao Gohma

    Department of Respiratory Medicine, Sakai City Medical Center, Sakai, Japan

    1 shared publication
  • Junya Kobayashi

    Department of Neurology, Sakai City Medical Center, Sakai, Japan

    1 shared publication
  • Kayo Ueda

    Department of Neurology and Pathology National Hospital Organization Osaka Toneyama Medical Center Toyonaka Japan

    1 shared publication
  • Keiko Toyooka

    Department of Neurology and Pathology National Hospital Organization Osaka Toneyama Medical Center Toyonaka Japan

    1 shared publication

Latest Publications

  • Open Access

    Familial ALS With p. L127S ( L126S ) Variant of the Cu/Zn SOD1 Gene: A Report of Two New Cases and Literature Review

    by Kimiko Inoue, Keiko Toyooka, Harutoshi Fujimura, Kayo Ueda, Misako Kaido, Yoichi Yamamoto, Yuishin Izumi

    Herein, we report two autopsy cases of familial ALS with a p. L127S (L126S) SOD1 variant. Case 1 involved a 62‐year‐old woman who presented with lower‐extremity muscle weakness with lower motor neuron signs. The patient developed bulbar palsy and died of respiratory failure 9 years after onset. Case 2 (the second son of Case 1) presented with lower‐extremity muscle weakness at the age of 38 years, with upper and lower motor neuron signs and died of respiratory failure 8 years after onset. The pathological findings in both cases predominantly consisted of lower motor neuron loss and degeneration of the lateral and posterior funiculi. Numerous conglomerate hyaline inclusions (CHIs) were observed in the remaining motor neurons. Vacuole formation was observed inside the inclusions, sometimes with granular structures. Some inclusions were positive for ubiquitin, p62, and SOD1. Electron microscopy revealed that CHIs were composed of neurofilaments and expanded mitochondria. By literature review, ALS with p. L127S disclosed a male‐dominant incidence rate, a variety of ages at onset, and low penetrance. The initial symptom was exclusively lower limb weakness. One‐third of the patients only showed lower motor neuron signs and half did not present with bulbar symptoms. The neuropathological findings commonly observed in ALS with p. L127S variants were mainly the degeneration of lower motor neurons and the sensory system, including the posterior column, Clarke's nucleus, and the associated cerebellar system. The formation of intracytoplasmic hyaline inclusions was also a prominent feature. ALS with p. L127S variant should be included in the possible diagnosis of slowly progressive muscle weakness in the lower extremities, with or without family history or upper motor neuron signs. The loss of lower motor neurons and the accumulation of neurofilaments in the remaining neurons are key to the pathological diagnosis for ALS with p. L127S variant.


  • Open Access

    Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male

    by Yoshiki Esa, Yuta Kajiyama, Misako Kaido, Yushi Watanabe, Harutoshi Fujimura, Iwao Gohma, Kenichi Takahashi, Junya Kobayashi

    April 2021 saw a widespread outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Osaka, Japan. We encountered the case of a 52-year-old man who had GuillainBarré syndrome associated with coronavirus disease 2019 (COVID-19). After the relief of the respiratory symptoms owing to COVID-19, the patient experienced muscle weakness, which spread from his fingers to his extremities, and was unable to walk. Further examinations revealed mild protein elevation in the cerebrospinal fluid. In addition, nerve conduction studies showed demyelinating polyneuropathy, leading to the diagnosis of GuillainBarré syndrome. After the administration of intravenous immunoglobulin and intravenous methylprednisolone, his symptoms drastically improved, and he was able to walk unaided 21 days after the onset of symptoms. On day 40, the patient was discharged with minimal muscle fatigue. Because GuillainBarré syndrome associated with COVID-19 is expected to have a good prognosis, early diagnosis and treatment are important. Therefore, GuillainBarré syndrome should be considered as a possible factor for muscle weakness during and after COVID-19 treatment.


  • A case of neuromyelitis optica spectrum disorder that relapsed with isolated intractable hiccup and nausea

    by Naoshi Koizumi, Yoshihito Yuasa, Misako Kaido, Masayasu Matsumoto

  • Female carrier with DMD mutation manifesting only asymptomatic hyperCKemia and psychiatric problems

    by Misako Kaido, Yoshihito Yuasa

    We report the case of a 64‐year‐old woman with dystrophinopathy exhibiting asymptomatic hyperCKemia and psychiatric symptoms only. Since adolescence, she had experienced communication difficulties and anxiety neurosis, which kept her unemployed and once led her to attempt suicide. Her full intelligence quotient was 89, with relatively low scores in processing speed and working memory, because of attention/concentration deficit or obsession. She has a nephew with severe dystrophinopathy, and both of them had duplication of exon 44 of the DMD gene, encoding dystrophin. Her mother became wheelchair user at age 60, and was suspected to have some psychiatric problems since she neglected her own ailing child. The cognitive and mental states of women with dystrophinopathy should be paid more attention to since such problems may manifest due to dystrophin deficit.